Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio’s clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapi...
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company’s board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. “Cheryl brings over three decades of leadership experience advancing the ...
Paramount Gold Commences Initial Assessment of Sleeper Gold Project in Nevada Advancing Evaluation of Potential Development Options WINNEMUCCA, Nev., April 09, 2026 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that it has commenced an Initial Assessment (“IA”) under the U.S. Securities and Exchange Commission (“SEC”) S-K 1300, for its 100%-owned Sleeper Gold Project (“Sleeper”), a past-producing high-grade gold mine located in Humboldt County, northern Nevada. The IA will be prepared in accordance with applicable U....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.